ASCO 2024 - Dr. Jean-Pierre Ayoub Reviews DESTINY-Breast06: Trastuzumab Deruxtecan's Impact on Progression-Free Survival

Join Dr. Jean-Pierre Ayoub as he reviews important results from the DESTINY-Breast06 trial. Learn how Trastuzumab Deruxtecan significantly improves progression-free survival in breast cancer patients previously treated with endocrine therapy. Discover the potential implications of these findings for patient care and treatment strategies.